66856001a.606

## CLAIMS

5 1. The use of galantamine or a derivative thereof of formula I:

15

20

25

10

wherein the broken line represents an optionally present double bond between carbon atoms 3 and 4, each R<sub>1</sub> is independently selected from hydrogen, hydroxyl, straight or branched chain alkyl, hydroxyalkyl, carboxyalkyl amino, alkylamino, acyl, lower alkanoyl, cyano, sulfhydryl, C<sub>1-6</sub>alkoxy, alkylthio, aryloxy, arylthio, R<sub>3</sub>-substituted aryloxy, R<sub>3</sub>-substituted arylthio, aralkoxy, an optionally R<sub>3</sub>-substituted aliphatic or aryl carbamyl group, aralkylthio, R<sub>3</sub>-substituted aralkoxy, R<sub>3</sub>-substituted aralkoxy, R<sub>3</sub>-substituted aralkylthio, aryloxymethyl, R<sub>3</sub>-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R<sub>3</sub>-substituted benzoyloxy, aryloxycarbonyl and R<sub>3</sub>-substituted aryloxycarbonyl,

30

35

 $R_2$  is selected from hydrogen, straight or branched chain  $C_{1-6}$ alkyl, alkenyl or alkaryl group, optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroaryl-alkyl, aryl, arylalkyl, cyano, amyl, aroyl, cycloalkylmethyl, allyl, phenyl,  $R_3$ -substituted phenyl, alkylphenyl,  $R_3$ -substituted alkylphenyl, heterocyclyl

selected from  $\alpha$ - or  $\beta$ -furyl,  $\alpha$ - or  $\beta$ -thienyl, thenyl, pyridyl, pyrazinyl, and pyrimidyl, alkyl-heterocyclyl or R'-substituted heterocyclyl, where R' is alkyl or alkoxy,

each R<sub>3</sub> is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, hydroxyalkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo, and trifluoromethyl,

each  $R_4$  is independently selected from hydrogen, halo, trifluoromethyl or  $C_{1-4}$ -alkyl,

each  $R_5$  is independently selected from hydrogen or hydroxymethyl,

 $R_6$  is hydrogen or  $C_{1-6}$ alkyl, or when  $R_1$  at carbon atom 2 is hydroxyl,  $R_6$  may be a moiety of formula I wherein  $R_6$  is hydrogen and  $R_1$  is a linking bond; or

 $\ensuremath{R_{1}}$  at carbon atom 2 and  $\ensuremath{R_{6}}$  may jointly form semicarbazone,

X is oxygen or NR3,

Y is nitrogen or phosphorus,

and methylenedioxy derivatives thereof and pharmaceutically acceptable acid addition salts thereof

in the manufacture of a medicament for combatting attention deficit disorders.

2. The use of galantamine or a derivative thereof of formula II

35

5

10

15

20

25

$$R_2O$$
 $R_4$ 
 $R_3$ 
 $R_4$ 
 $R_3$ 

wherein R<sup>1</sup> and R<sup>2</sup> which may be the same or different each represents a hydrogen atom or an acyl group, such as a lower alkanoyl group, e.g. an acetyl group or a straight-chained or branched alkyl group, e.g. methyl, ethyl, propyl, or isopropyl;

5

10

15

30

35

R<sup>3</sup> is a straight or branched chain alkyl, alkenyl or alkaryl group which is optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroarylalkyl, aroyl, aroylalkyl or cyano group; and

 $R^4$  represents a hydrogen or a halogen atom attached to at least one of the ring carbons of the tetracyclic skeleton,

and pharmaceutically acceptable salts thereof, such as a hydrobromide, hydrochloride, methylsulphate or methiodide in the manufacture of a medicament for combatting attention deficit disorders.

The use of galantamine or a salt thereof in the manufacture of a medicament for combatting attention

deficit disorders.

25 4. The use is claimed in any one of claims 1 to 3 wherein the disorder is attention deficit hyperactivity disorder.

- 5. The use as claimed in any one of claims 1 to 3 wherein the disorder is a hyperkinetic disorder.
  - 6. A method of combatting attention deficit disorders comprising administering galantamine or a salt or derivative thereof as defined in claim 1 or claim 2.
  - 7. A method as claimed in claim 6 wherein the disorder is as defined in claim 4 or claim 5.